Mp53-15 Prediction of Prognosis by B Cell Axis in Patients With Muscle-Invasive Bladder Cancer Undergoing Open Radical Cystectomy

You have accessJournal of UrologyBladder Cancer: Invasive V (MP53)1 May 2024MP53-15 PREDICTION OF PROGNOSIS BY B CELL AXIS IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING OPEN RADICAL CYSTECTOMY Laila Schneidewind, Uwe Grunwald, Thomas Neumann, Oliver W. Hakenberg, and Bernhard Kiss Laila SchneidewindLaila Schneidewind , Uwe GrunwaldUwe Grunwald , Thomas NeumannThomas Neumann , Oliver W. HakenbergOliver W. Hakenberg , and Bernhard KissBernhard Kiss View All Author Informationhttps://doi.org/10.1097/01.JU.0001008784.37684.bd.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cancer immunotherapy, the game changer in muscle-invasive bladder cancer (MIBC), is predominately based on T cell-mediated approaches. At the same time, the adaptive immune response in the tumor also includes effector B cells that participate in the antigen-specific reactions through their interactions with T cells. Consequently, we performed a pilot study in patients with MIBC undergoing open radical cystectomy (RC) analyzing pre-operative cellular immune phenotyping of peripheral blood and tumor-infiltrating immune cells. This analysis is focused on B cell axis. METHODS: After a positive vote of ethical review committee, we started a prospective clinical non-interventional study including those patients. Pre-operative cellular immune phenotyping was done via FACS and tumor-infiltrating immune cells were isolated from tumor tissue and also analyzed via FACS. So far, we were able to include 15 patients. Additionally, all relevant clinical data were collected. Statistical analysis was performed using SPSS 28.0. RESULTS: Fifteen patients with a median age of 70.0 years (IQR 58.0 – 73.0) were included, twelve (80.0%) were male and three (20.0%) were female. Regarding the pathological stage of MIBC, 3 patients (20.0%) had pTis, 1 patient (6.7%) pT2a, 1 patient (6.7%) pT3a, 6 patients (40.0%) pT3b, 3 patients (20.0%) pT4a and 1 patient (6.7%) pT4b disease. Furthermore, 7 patients (46.7%) had lympho-vascular infiltration, 10 patients (66.7%) had lymph node metastasis. Two patients (13.4%) received palliative RC due to distant metastasis. Concerning B cell axis, relative shortage of B cells (lower than 5.9 %) in peripheral blood preoperatively is significantly associated with metastatic disease (p=0.003). Additionally, relative shortage of B cells in peripheral blood preoperatively is significantly associated with death (p=0.008) and high percentage of plasmablasts (higher than 10% of B cells) in tumor tissue is also associated with death (p=0.029). Interestingly, these prognostic findings are independent from prior neoadjuvant chemotherapy. So far, the median survival is 6 months (IQR 4.0 – 15.0). CONCLUSIONS: Relative shortage of B cells prior to RC might be associated with metastatic disease as well as poor prognosis and high percentage of plasmablasts in the tumor microenvironment might also be predictive for poor survival. B cells axis needs further evaluation in MIBC. This might reveal interesting biomarkers and new therapeutic targets. Source of Funding: No external funding received © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e869 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Laila Schneidewind More articles by this author Uwe Grunwald More articles by this author Thomas Neumann More articles by this author Oliver W. Hakenberg More articles by this author Bernhard Kiss More articles by this author Expand All Advertisement PDF downloadLoading ...